Shorts

First Assist: The evolving role of cystectomy in bladder cancer

Closing the gap: Urologists and female sexual health

Testosterone and prostate cancer risk: A balanced message

Beyond cisplatin eligibility: A new MIBC standard

Anatomy vs function: What reconstruction really means

The role of focal therapy in an evolving prostate cancer landscape

Michael Uy, MD on the impact of unmet social needs in kidney stone disease

Urocross: The case for a retrievable BPH device

Ravi Munver, MD, on AI-guided treatment planning with the HYDROS system

What urologists need to know before using Break Wave

Hans Arora, MD, PhD, on the most critical factor in surgical team performance

Why TRT Is no longer a blanket denial for cardiac risk

Patient selection for perioperative treatment in high-risk localized prostate cancer

Heat, plastic, and exposure: What patients should know

Vivian Wan, MD, on the value of mapping biopsies for CIS detection

FDA testosterone label updates: 2 meaningful changes

EV-302 response rates put surgical consolidation in context

Amy E. Krambeck, MD, outlines anatomic enucleation course

Daniel J. George, MD, on the significance of capivasertib for PTEN-deficient mHSPC

What it takes to move the needle on urologic patient safety

Why patients choose Break Wave over URS

Jenny N. Guo, MD, on key BPH takeaways from AUA 2026

Joy Maulik, CRNP, highlights LUGPA Advanced Practice Provider Forum

The UroOnc Minute: Patient selection for MDT in the PSMA-PET era

Archan Khandekar, MD, on the future for AI in urology

Praful Ravi, MB, BChir, MRCP, on residual disease detection using PSMA-PET

What BULLSEYE's PFS data should—and shouldn't—mean

Why Break Wave Lithotripsy is a game changer for stone care

Aleece Fosnight, MSPAS, PA-C, on what to tell patients about microplastics and bladder health

Louise Emmett, MD, PhD, MBChB, FRACP, on the potential role of 225Ac-PSMA-617 earlier in mCRPC